Ming-Ming He

Evaluation of <i>POLE</i> and <i>POLD1</i> Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types

Feng Wang, Qi Zhao, Ying-Nan Wang et al. · JAMA Oncology · 2019 · 441 citations · Full text

Medicine, Oncology, Health Services Research +9

Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis

Feng Wang, Ming-Ming He, Xia Zhao et al. · Cell Reports Medicine · 2021 · 170 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio

Xiaoli Wei, Feng‐Hua Wang, Dongsheng Zhang et al. · BMC Cancer · 2015 · 160 citations · Full text

Medicine, Oncology, Pathology +17

Immune-Mediated Diseases Associated With Cancer Risks

Ming-Ming He, Chun‐Han Lo, Kai Wang et al. · JAMA Oncology · 2021 · 145 citations · Full text

Medicine, Immunology, Oncology +11

Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers

Hao‐Xiang Wu, Zixian Wang, Qi Zhao et al. · Annals of Translational Medicine · 2019 · 133 citations · Full text

Medicine, Immunology, Oncology +17